0001193125-19-104586.txt : 20190412 0001193125-19-104586.hdr.sgml : 20190412 20190412083055 ACCESSION NUMBER: 0001193125-19-104586 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190412 DATE AS OF CHANGE: 20190412 EFFECTIVENESS DATE: 20190412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNE DESIGN CORP. CENTRAL INDEX KEY: 0001437786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262007174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36561 FILM NUMBER: 19745270 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE E. STREET 2: SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (650) 392-8350 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: SUITE 250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Immune Design Corp. DATE OF NAME CHANGE: 20090702 FORMER COMPANY: FORMER CONFORMED NAME: VACCSYS INC DATE OF NAME CHANGE: 20080617 15-12B 1 d734731d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-36561

 

 

IMMUNE DESIGN CORP.

(Exact name of registrant as specified in its charter)

 

 

1616 Eastlake Ave. E., Suite 310

Seattle, Washington 98102

(206) 682-0645

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   ☐
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☒
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐
Rule 15d-22(b)   ☐

Approximate number of holders of record as of the certification or notice date: One (1)*

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Immune Design Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

            IMMUNE DESIGN CORP.
Date:    April 12, 2019     By:   /s/ Faye C. Brown
      Name: Faye C. Brown
      Title:   Assistant Secretary

 

*

On April 2, 2019, pursuant to the Agreement and Plan of Merger, dated as of February 20, 2019, by and among Immune Design Corp. (the “Company”), Merck Sharp & Dohme Corp., a New Jersey corporation (the “Parent”) and Cascade Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the “Purchaser”), the Purchaser merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent.

Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.